香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 本 公 告 僅 供 參 考，並 不 構 成 收 購、購 買 或 認 購 本 公 司 證 券 的 邀 請 或 要 約。 若 構 成 違 反 任 何 司 法 權 區 的 適 用 法 律 或 規 例，則 本 公 告 所 載 全 部 或 部 分 資 料 不 得 於 或 向 該 司 法 權 區 發 佈、刊 發 或 派 發。 WUXI XDC CAYMAN INC. 藥明合聯生物技術有限公司* （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：2268） BioDlink International Company Limited 東曜藥業股份有限公司 （於 香 港 註 冊 成 立 的 有 限 公 司） （股份代號：1875） 聯合公告 寄發有關 花旗環球金融亞洲有限公司為及代表要約人 就本公司全部已發行股份 （要 約 人 及 要 ...

東曜藥業股份有限公司 Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this WHITE Form of Share Offer Acceptance, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this WHITE Form of Share Offer Acceptance. 香港交易及結算所有限公司、香港聯合交易所有限公司及香港中央結算有限公司對本 ...

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this PINK Form of Option Offer Acceptance, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this PINK Form of Option Offer Acceptance. 香港交易及結算所有限公司、香港聯合交易所有限公司及香港中央結算有限公司對本 粉紅色 購股權要約接 ...

此乃要件 請即處理 閣下如 對要約、本綜合文件及╱或隨附之接納表格任何方面或應採取之行動 有任何疑問，應諮詢持牌證券交易商或註冊 證券機構、銀行經理、律師、專業會計師或其他專業顧問。 閣下如已售出 或以其他方式轉讓所有名下之 東曜藥業股份有限公司 證券，應立即將本綜合文件連同隨附之接納表格送交 買方或承讓人，或經手買賣或轉讓之持牌證券交易商或註冊證券機構、銀行或其他代理商，以便轉交買方或承讓人。 本綜合文件應與隨附之接納表格一併閱讀，表格之內容構成要約條款及條件之一部分。本綜合文件不會於或向任何倘此 舉屬違反當地相關法例的司法權區發佈、刊發或派發。 香港交易及結算所有限公司、香港聯合交易所有限公司及香港中央結算有限公司對本綜合文件及隨附之接納表格之內容 概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本綜合文件及隨附之接納表格全部或任何部分 內容而產生或因依賴該等內容而引致之任何損失承擔任何責任。 本綜合文件未經美國證券交易委員會或任何美國州證券委員會批准、否決或以其他方式作出推薦，上述機構並未批准或 否決要約，亦未確認本綜合文件的充分性或準確性。任何與上述內容相反的陳述均會在美國構成刑事犯罪 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告內容概不負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 份 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 本 公 告 僅 供 參 考，並 不 構 成 收 購、購 買 或 認 購 本 公 司 證 券 的 邀 請 或 要 約。 本公告的全部或部份內容不會在違反任何司法權區的相關法律或法規的情況 下 於 或 向 該 司 法 權 區 發 佈、刊 發 或 派 發。 （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （於 香 港 註 冊 成 立 的 有 限 公 司） （股 份 代 號：2268） （股 份 代 號：1875） 聯合公告 延遲寄發 有 關 花旗環球金融亞洲有限公司為及代表要約人 就本公司全部已發行股份 （要 約 人 及 要 約 人 一 致 行 動 人 士 已 擁 有 或 同 意 將 予 收 購 的 該 等 股 份 除 外） 及註銷全部尚未行使購股權 而作出的 自願有條件現金要約 的 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2026年1月31日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 東曜藥業股份有限公司 | | | 呈交日期: | 2026年2月4日 | | | I. 法定/註冊股本變動 不適用 | | | FF301 第 1 頁 共 10 頁 v 1.2.0 FF301 II. 已發行股份及/或庫存股份變動及足夠公眾持股量的確認 1. 股份分類 普通股 股份類別 不適用 於香港聯交所上市 (註1) 是 證券代號 (如上市) 01875 說明 已發行股份（不包括庫存股份）數目 庫存股份數目 已發行股份總數 上月底結存 772,787,887 0 772,787,887 增加 / 減少 (-) 0 0 本月底結存 772,787,887 0 772,787,887 足夠公眾持股量的確認(註4) | 根據《主板上市規則》第13.32D(1)條或第19A.28D(1)條 / 《GEM上市規則》第17.37D(1)條或第25.21D(1)條，我們在 ...

Group 1 - The pharmaceutical and biotechnology industry is experiencing active consolidation and collaboration, with significant acquisitions and partnerships announced recently [1] - China National Pharmaceutical Group announced a full acquisition of Hejiya Biotech for 1.2 billion RMB, gaining access to its leading technology platform and diverse product pipeline [1] - Rongchang Biotech entered an exclusive licensing agreement with AbbVie for the bispecific antibody RC148, receiving an upfront payment of 650 million USD and potential milestone payments [1] Group 2 - WuXi AppTec announced plans to acquire all issued shares of Dongyao Pharmaceutical for approximately 2.79 billion HKD [1] - The Ministry of Commerce and nine other departments released guidelines to promote high-quality development in the pharmaceutical retail industry, focusing on transformation, payment, supply, and integration [1] - The policy encourages mergers and acquisitions, aiming to shift the industry from a "single drug sales" model to a "health service" model, which is expected to accelerate the clearing of individual pharmacies and increase industry concentration [1]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" and the rating has been maintained [2] Core Insights - The pharmaceutical and biotechnology industry index experienced a decline of 1.07%, ranking 26th among 31 primary industries, outperforming the CSI 300 index which fell by 1.19% [4][15] - The valuation of the pharmaceutical and biotechnology industry as of January 23, 2026, is a PE (TTM overall method, excluding negative values) of 30.31x, down from 30.56x in the previous period, indicating a downward trend below the average [4][19] - The top three sub-industries by PE are vaccines (47.34x), hospitals (44.94x), and other medical services (40.38x), while the lowest valuation is in pharmaceutical circulation (15.31x) [4][19] - During the reporting period, 34 listed companies in the pharmaceutical and biotechnology sector saw a net reduction of 2.125 billion yuan in shareholder holdings, with 2 companies increasing holdings by 63 million yuan and 32 companies reducing holdings by 2.189 billion yuan [4] Industry Review - The report highlights significant developments in the pharmaceutical retail sector, emphasizing the need for transformation from traditional drug sales to comprehensive health services [24][25] - The Ministry of Commerce and other departments issued opinions to promote high-quality development in the pharmaceutical retail industry, projecting a market size increase from 2.41 trillion yuan in 2020 to 2.95 trillion yuan by 2024, a growth of 22.4% [24][25] - The report also discusses the approval of new drugs and treatments, including the PD-1/VEGF bispecific antibody RC148 by Rongchang Biopharmaceuticals, which has a potential total payment of up to 4.95 billion USD [7][50] Investment Recommendations - The report suggests focusing on innovative pharmaceutical companies with differentiated pipelines that have received validation from high-quality collaborations with multinational pharmaceutical companies, particularly in key areas such as ADC, bispecific antibodies, and siRNA therapies [7]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" and the rating has been maintained [2] Core Insights - The pharmaceutical and biotechnology industry index experienced a decline of 1.07%, ranking 26th among 31 primary industries, outperforming the CSI 300 index which fell by 1.19% [4][15] - The valuation of the pharmaceutical and biotechnology industry as of January 23, 2026, is a PE (TTM overall method, excluding negative values) of 30.31x, down from 30.56x in the previous period, indicating a decline in valuation below the average [4][19] - The top three sub-industries by PE (TTM overall method, excluding negative values) are vaccines (47.34x), hospitals (44.94x), and other medical services (40.38x), while the lowest valuation is in pharmaceutical circulation (15.31x) [4][19] - During the reporting period, 34 listed companies in the pharmaceutical and biotechnology sector saw a net reduction in shareholder holdings amounting to 2.125 billion yuan, with 2 companies increasing holdings by 63 million yuan and 32 companies reducing holdings by 2.189 billion yuan [4] Industry Trends - The 2026 JPM Conference highlighted Chinese innovative drugs as a global focus, with several Chinese companies showcasing advancements in PD-1/VEGF bispecific antibodies, ADCs, and cell therapies [7] - The report suggests focusing on innovative pharmaceutical companies with differentiated pipelines that have received validation through high-quality collaborations with multinational pharmaceutical companies, particularly in key areas such as ADCs, bispecific antibodies, and siRNA therapies [7] Important Industry News - The Ministry of Commerce and eight other departments issued opinions on promoting high-quality development in the drug retail industry, projecting a growth in the drug circulation market from 2.41 trillion yuan in 2020 to 2.95 trillion yuan by 2024, a 22.4% increase [24] - The National Healthcare Security Administration released guidelines for pricing projects related to surgical and treatment auxiliary operations, aiming to standardize and promote the use of advanced medical technologies [27][28] - Notable approvals include Daiichi Sankyo's "Trastuzumab Deruxtecan" for advanced HER2-positive gastric cancer, and AbbVie’s "Risankizumab" for ulcerative colitis, showcasing significant advancements in treatment options [38][44]

报告指，2025年上半年，东曜药业录得收入4.89亿元人民币(下同)，盈利400万元;同期对比，药明合联 的收入和盈利分别为27.01亿元及7.46亿元。过去，东曜药业专注于肿瘤药物，进入2020年代后，公司将 资源重新配置，转型为以ADC(抗体-药物偶联物)为重点的CDMO模式。 摩根士丹利发布研报称，药明合联(02268)提全购东曜药业-B(01875)，交易引起部分投资者对收购理据 的疑问。大摩对药明合联评级为"增持"，目标价88港元。 ...